April 10, 2021

Theratechnologies Presents New In Vivo Pre-Clinical Data At AACR Demonstrating Significant Anti-Tumor Activity Of TH1902 In All Studied Cancer Types

TH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone

 Montreal, Canada – April 10, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that new in vivo preclinical data were presented at the 2021 Annual Meeting of the American Association for Cancer Research (AACR). These data demonstrated sustained tumor regression, better anti-tumor activity and tolerability with TH1902 compared to docetaxel alone in all cancer types studied, namely melanoma, pancreatic, ovarian, endometrial, colorectal and triple-negative breast cancers. The anti-tumor effect of TH1902 persisted longer post-treatment than with docetaxel alone. TH1902 is the Company’s lead investigational peptide-drug conjugate (PDC) derived from its SORT1+ Technology™.

“The FDA fast-track designation for TH1902 was supported by the data presented today. This designation is a significant recognition of our SORT1+ Technology™ as very few investigational therapies receive fast track designation based on preclinical data. It strongly endorses TH1902 as a potentially new and innovative treatment for all patients with sortilin positive (SORT1+) solid tumors that are refractory to standard therapy.  The Phase 1 clinical trial is now underway and we look forward to advancing TH1902 through further stages of its development,” said Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies.

For the complete version, please download the PDF document.